Active, not recruitingPhase 3NCT05394116
A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)
Studying Fibrodysplasia ossificans progressiva
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Regeneron Pharmaceuticals
- Principal Investigator
- Clinical Trial ManagementRegeneron Pharmaceuticals
- Intervention
- Garetosmab(drug)
- Enrollment
- 63 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2029
Study locations (22)
- University of California Los Angeles (UCLA) Medical Center, Los Angeles, California, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- Royal North Shore Hospital, St Leonards, New South Wales, Australia
- Hospital Israelita Albert Einstein, São Paulo, Brazil
- Universidad de Concepcion, Concepción, Bio Bio, Chile
- Tongji Hospital of Tongji University, Shanghai, China
- Clinica Universidad de La Sabana, Chía, Cundinamarca, Colombia
- HUS Children and Adolescents Park Hospital Clinical Trial Unit, Helsinki, Stenbäckinkatu 11, Finland
- Hôpital Lapeyronie, Montpellier, France
- Hopital Lariboisiere, Paris, France
- Queen Mary Hospital, Hong Kong, Hong Kong
- IRCCS Istituto Giannina Gaslini, Genoa, Italy
- Nagoya University Hospital, Nagoya, Aichi-ken, Japan
- Oita University Hospital, Yufu, Oita Prefecture, Japan
- Kyushu University Hospital, Fukuoka, Japan
- +7 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05394116 on ClinicalTrials.govOther trials for Fibrodysplasia ossificans progressiva
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06724562IL1 Inhibition in FOPUniversity of California, San Francisco
- RECRUITINGNCT06089616A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)Ipsen
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT06508021A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)Ashibio Inc
- RECRUITINGPHASE2NCT05090891To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans ProgressivaIncyte Corporation
- RECRUITINGNCT02745158The Fibrodysplasia Ossificans Progressiva (FOP) Connection RegistryThe International FOP Association